Total Funding
35
63
Total FundingGrant raised
Growth Score
-4 pts
Heat Score
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
62692
KYAN Therapeutics is a clinical-stage AI company leveraging its proprietary technology platforms to transform the way patients are treated.
- Hugo Saavedra: Chief Executive Officer
- Edward Chow: Non Executive Director, Co-Founder
About the Company
KYAN Therapeutics is a clinical-stage artificial intelligence company leveraging its proprietary technology platforms to transform the way patients are treated and therapies are developed. KYAN is able to revolutionize the drug development and dosage optimization processes and has multiple pipeline combination therapies in development for oncology
and infectious diseases.
KYAN de-risks and dramatically accelerates the drug development process, identifying novel combination therapies with unprecedented efficacy and safety. KYAN's clinically-validated platforms are uniquely disease-mechanism and indication agnostic.
